Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  JP Morgan Chase & Company    JPM

JP MORGAN CHASE & COMPANY

(JPM)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Exclusive: JPMorgan cuts ties with OxyContin maker Purdue Pharma - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2019 | 09:11pm EDT
FILE PHOTO: Bottles of prescription painkiller OxyContin made by Purdue Pharma LP on a counter at a local pharmacy in Provo

(Reuters) - JPMorgan Chase & Co has cut ties with Purdue Pharma LP over the OxyContin maker's alleged role in the U.S. opioid crisis, forcing it to find a new bank to manage cash and bill payments, people familiar with the matter said on Thursday.

The move makes JPMorgan, the largest U.S. bank by assets, the most high-profile corporation known to have distanced itself from Purdue and its wealthy owners, the Sackler family, amid thousands of lawsuits alleging the company pushed addictive painkillers while downplaying their abuse and overdose risks.

JPMorgan's decision also underscores a drive among U.S. banks to reassess their relationships with clients and industries in response to controversy and political debates over matters such as immigration detention and mass shootings.

After JPMorgan informed Purdue in March that it had six months to find another bank, Purdue tapped Dallas-based regional bank Comerica Inc to handle its financial transactions and accounts, the sources said.

JPMorgan told Purdue that reputational risks associated with the public backlash against the drugmaker informed its decision to cut business ties, the sources added.

While not a lender to Purdue, JPMorgan's commercial bank managed the company's cash and bill payments, according to the sources. It is not clear how long JPMorgan served as Purdue's bank.

"Purdue is a streamlined organization with an exciting pipeline of new medicines and significant cash reserves," the company said in a statement. "The company has multiple banking relationships and will not have any interruption to its banking and financial service needs."

JPMorgan and Comerica declined to comment.

Purdue faces roughly 2,000 lawsuits accusing the Stamford, Connecticut-based company, and increasingly the Sacklers, of aggressively marketing prescription opioids while misleading prescribers and consumers about risks from their prolonged use.

U.S. states, counties and cities are seeking billions of dollars in damages to address harm from opioids. Nearly 400,000 people have died after overdosing on opioids between 1999 and 2017, according to the latest data from the U.S. Centers for Disease Control and Prevention. More than half the deaths resulted from prescription painkillers.

Purdue denies it contributed to the U.S. opioid crisis, pointing to U.S. Food and Drug Administration approvals of labels for the company's drugs that carried warnings about risk and abuse associated with treating pain. Purdue and its family owners argue that heroin and fentanyl are currently more significant culprits in the opioid epidemic.

However, health experts have said many people turn to those drugs after first getting hooked on prescription painkillers.

In March, Purdue and the Sackler family reached a $270 million settlement with the state of Oklahoma, which on Tuesday is set to take two other drugmakers to trial over claims they also helped fuel the opioid epidemic. Dozens of other states have lawsuits pending against Purdue, and in some instances the Sacklers, who made a financial contribution to the Oklahoma settlement even though they were not defendants in the case.

A North Dakota judge earlier this month dismissed that state's case against Purdue.

Purdue Chief Executive Officer Craig Landau in March said a bankruptcy filing remained an option for the company to address potential liabilities from widespread litigation.

LATEST TO SHUN

Various museums, universities and other nonprofits are now shunning donations or reassessing their relationships with the Sackler family, which has a long history of philanthropy.

In New York, The Metropolitan Museum of Art, which has a wing named for the Sacklers, and the American Museum of Natural History, said earlier this month they had ceased accepting donations from the family.

For JPMorgan, dropping Purdue is the latest in a series of moves aimed at steering clear of political lightning rods. In January, the bank said it would stop financing operators of private prisons, which have become the target of protests over their role detaining undocumented immigrants.

Its peers have made similar moves. In March, Wells Fargo & Co's CEO at the time, Tim Sloan, told a congressional panel the bank was exiting relationships with private prison operators.

Citigroup Inc, meanwhile, last year placed restrictions on firearms sales for retailers doing business with the bank following the deadly school shooting in Parkland, Florida. A Bank of America Corp executive said last year that the bank intended to avoid financing military-style firearms for civilians moving forward.

(Reporting by Mike Spector and Jessica DiNapoli in New York; Additional reporting by David Henry in New York; Editing by Greg Roumeliotis and Bill Berkrot)

By Mike Spector and Jessica DiNapoli

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JP MORGAN CHASE & COMPANY
03:43aFormer JPMorgan senior banker pleads not guilty to HK bribery charges
RE
03:43aFormer JPMorgan senior banker pleads not guilty to Hong Kong bribery charges
RE
02:50aConsumers Lift Bank of America Profit -- WSJ
DJ
07/17JP MORGAN CHASE MPANY : Former JPMorgan senior banker pleads not guilty to HK br..
RE
07/17BRIAN MOYNIHAN : Bank of America trims net interest income guidance
RE
07/17Trade, earnings worry drag on stocks; U.S. Treasury yields fall
RE
07/17Trade, earnings worry drag on global stocks; U.S. Treasury yields fall
RE
07/17Consumers Lift Profit at Bank of America -- 3rd Update
DJ
07/17U.S. Bancorp Reports Higher Earnings
DJ
07/17Wall Street finds blockchain hard to tame after early euphoria
RE
More news
Financials (USD)
Sales 2019 113 B
EBIT 2019 47 893 M
Net income 2019 32 660 M
Debt 2019 -
Yield 2019 2,98%
P/E ratio 2019 11,3x
P/E ratio 2020 10,9x
Capi. / Sales2019 3,26x
Capi. / Sales2020 3,21x
Capitalization 370 B
Chart JP MORGAN CHASE & COMPANY
Duration : Period :
JP Morgan Chase & Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JP MORGAN CHASE & COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 118,88  $
Last Close Price 113,99  $
Spread / Highest target 22,8%
Spread / Average Target 4,29%
Spread / Lowest Target -25,4%
EPS Revisions
Managers
NameTitle
James Dimon Chairman & Chief Executive Officer
Gordon A. Smith Co-President & Co-Chief Operating Officer
Daniel E. Pinto Co-President & Co-Chief Operating Officer
Yan Tavrovsky President & Chairman-Management Board
Marianne Lake Chief Financial Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
JP MORGAN CHASE & COMPANY17.93%369 727
INDUSTRIAL AND COMMERCIAL BANK OF CHINA6.05%279 743
BANK OF AMERICA17.65%279 161
WELLS FARGO & COMPANY-1.69%211 863
CHINA CONSTRUCTION BANK CORPORATION12.72%200 723
HSBC HOLDINGS PLC2.69%168 727